The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biologics from companies like Biogen, Amgen, and AstraZeneca are broadening treatment options, with key drugs such as Litifilimab and Daxdilimab advancing in clinical trials. The U.S. leads the market, holding 60% of diagnosed cases, and antimalarials currently dominate treatment revenue. These emerging therapies are expected to transform patient care and market dynamics in the coming decade.
Biogen is under investigation by Pomerantz LLP for potential securities fraud following the announcement that its Alzheimer's drug trial missed the primary dose-response endpoint, despite being described as "compelling." The news caused Biogen's stoc...
New modeling from Boehringer Ingelheim's FIBRONEER™ Phase III trials suggests that nerandomilast, an oral PDE4B inhibitor, could significantly extend median survival in adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosi...
Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase ...
